α-Defensins in human innate immunity

Immunological Reviews

Volumn 245, Issue 1, 2012, Pages 84-112

  Lehrer, Robert I ^a   Lu, Wuyuan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial peptides; Defensins; Innate immunity; Neutrophil; Paneth cells

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; CYSTEINE; HISTONE; IMMUNOGLOBULIN G ANTIBODY;

ADENOVIRUS INFECTION; CANDIDIASIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROHN DISEASE; CRYSTAL STRUCTURE; DISULFIDE BOND; EVOLUTION; GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; INFLUENZA A; INNATE IMMUNITY; INVERTEBRATE; LEUKOCYTE; MEMORY T LYMPHOCYTE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PANETH CELL; PRIMATE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RESPIRATORY TRACT INFECTION; REVIEW; VIRAL CONJUNCTIVITIS; X RAY CRYSTALLOGRAPHY;

ALPHA-DEFENSINS; ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL EVOLUTION; COMPUTATIONAL BIOLOGY; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; NEUTROPHILS; PANETH CELLS; PROTEIN CONFORMATION;

EID: 83655193502     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01082.x     Document Type: Review

References (370)

1. Belarmino LC, Capriles PV, Crovella S, Dardene LE, Benko-Iseppon AM. EST-database search of plant defensins - an example using sugarcane, a large and complex genome. Curr Protein Pept Sci 2010;11:248-254.
2. Zhu S. Discovery of six families of fungal defensin-like peptides provides insights into origin and evolution of the CSalphabeta defensins. Mol Immunol 2008;45:828-838.
3. Zhu S. Evidence for myxobacterial origin of eukaryotic defensins. Immunogenetics 2007;59:949-954.
4. Gerdol M, DeMoro G, Manfrin C, Venier P, Pallavicini A. Big defensins and mytimacins, new AMP families of the Mediterranean mussel Mytilus galloprovincialis. Dev Comp Immunol 2011, doi:.
5. Isogai E, Isogai H, Okumura K, Hori H, Tsuruta H, Kurebayashi Y. Tertiary structure-related activity of tick defensin (persulcatusin) in the taiga tick, Ixodes persulcatus. Exp Appl Acarol 2011;53:71-77.
6. Mygind PH, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 2005;437:975-980.
7. Gachomo EW, Jimenez-Lopez JC, Kayode AP, Baba-Moussa L, Kotchoni SO. Structural characterization of plant defensin protein superfamily. Mol Biol Rep 2011, doi:.
8. Iwanaga S, Kawabata S, Muta T. New types of clotting factors and defense molecules found in horseshoe crab hemolymph: their structures and functions. J Biochem 1998;123:1-15.
9. Saito T, et al. A novel big defensin identified in horseshoe crab hemocytes: isolation, amino acid sequence, and antibacterial activity. J Biochem 1995;117:1131-1137.
10. Kawabata S, et al. cDNA cloning tissue distribution and subcellular localization of horseshoe crab big defensin. Biol Chem 1997;378:289-292.
11. Selsted ME, Harwig SS. Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide. J Biol Chem 1989;264:4003-4007.
12. Pestarino M, Oliveri D, Parodi M, Candiani S. The amphioxus immune system. ISJ 2007;4:45-50.
13. Fedders H, Leippe M. A reverse search for antimicrobial peptides in Ciona intestinalis: identification of a gene family expressed in hemocytes and evaluation of activity. Dev Comp Immunol 2008;32:286-298.
14. Lee IH, Cho Y, Lehrer RI. Styelins, broad-spectrum antimicrobial peptides from the solitary tunicate, Styela clava. Comp Biochem Physiol B Biochem Mol Biol 1997;118:515-521.
15. Lee IH, Zhao C, Cho Y, Harwig SS, Cooper EL, Lehrer RI. Clavanins, alpha-helical antimicrobial peptides from tunicate hemocytes. FEBS Lett 1997;400:158-162.
16. Lee IH, Cho Y, Lehrer RI. Effects of pH and salinity on the antimicrobial properties of clavanins. Infect Immun 1997;65:2898-2903.
17. Tincu JA, et al. Plicatamide an antimicrobial octapeptide from Styela plicata hemocytes. J Biol Chem 2003;278:13546-13553.
18. Zhao C, Liaw L, Lee IH, Lehrer RI. cDNA cloning of Clavanins: antimicrobial peptides of tunicate hemocytes. FEBS Lett 1997;410:490-492.
19. Herve-Grepinet V, et al. Purification and characterization of avian beta-defensin 11, an antimicrobial peptide of the hen egg. Antimicrob Agents Chemother 2010;54:4401-4409.
20. Yudin AI, Treece CA, Tollner TL, Overstreet JW, Cherr GN. The carbohydrate structure of DEFB126, the major component of the cynomolgus Macaque sperm plasma membrane glycocalyx. J Membr Biol 2005;207:119-129.
21. Khanna R, Burrows SR. Human immunology: a case for the ascent of non-furry immunology. Immunol Cell Biol 2011;89:330-331.
22. Patil AA, Cai Y, Sang Y, Blecha F, Zhang G. Cross-species analysis of the mammalian beta-defensin gene family: presence of syntenic gene clusters and preferential expression in the male reproductive tract. Physiol Genomics 2005;23:5-17.
23. Maxwell AI, Morrison GM, Dorin JR. Rapid sequence divergence in mammalian beta-defensins by adaptive evolution. Mol Immunol 2003;40:413-421.
24. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002;23:291-296.
25. Tollner TL, et al. A common mutation in the defensin DEFB126 causes impaired sperm function and subfertility. Sci Transl Med 2011;3:1-9.
26. Zou J, Mercier C, Koussounadis A, Secombes C. Discovery of multiple beta-defensin like homologues in teleost fish. Mol Immunol 2007;44:638-647.
27. Jin JY, et al. Antibacterial and antiviral roles of a fish beta-defensin expressed both in pituitary and testis. PLoS ONE 2010;5:e12883.
28. Dalla Valle L, Benato F, Maistro S, Quinzani S, Alibardi L. Bioinformatic and molecular characterization of beta-defensins-like peptides isolated from the green lizard Anolis carolinensis. Dev Comp Immunol 2011;36:222-229.
29. Abdel Mageed AM, Isobe N, Yoshimura Y. Immunolocalization of avian beta-defensins in the hen oviduct and their changes in the uterus during eggshell formation. Reproduction 2009;138:971-978.
30. Sugiarto H, Yu PL. Avian antimicrobial peptides: the defense role of beta-defensins. Biochem Biophys Res Commun 2004;323:721-727.
31. Rudkin DM, Young GA, Nowlan GS. The oldest horseshoe crab: a new xiphosurid from Late Oordovician Konservat-Lagerstatten deposits, Manitoba, Canada. Paleontology 2008;51:1-9.
32. Diamond G, Zasloff M, Eck H, Brasseur M, Maloy WL, Bevins CL. Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc Natl Acad Sci USA 1991;88:3952-3956.
33. Selsted ME, et al. Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils. J Biol Chem 1993;268:6641-6648.
34. Bensch KW, Raida M, Magert HJ, Schulz-Knappe P, Forssmann WG. hBD-1: a novel beta-defensin from human plasma. FEBS Lett 1995;368:331-335.
35. Ganz T, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985;76:1427-1435.
36. Selsted ME, Brown DM, DeLange RJ, Harwig SS, Lehrer RI. Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils. J Biol Chem 1985;260:4579-4584.
37. Tang YQ, et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 1999;286:498-502.
38. Amid C, et al. Manual annotation and analysis of the defensin gene cluster in the C57BL/6J mouse reference genome. BMC Genomics 2009;10:606.
39. Linzmeier R, Ho CH, Hoang BV, Ganz T. A 450-kb contig of defensin genes on human chromosome 8p23. Gene 1999;233:205-211.
40. Liu L, Zhao C, Heng HH, Ganz T. The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics 1997;43:316-320.
41. Lynn DJ, Bradley DG. Discovery of alpha-defensins in basal mammals. Dev Comp Immunol 2007;31:963-967.
42. Belov K, et al. Characterization of the opossum immune genome provides insights into the evolution of the mammalian immune system. Genome Res 2007;17:982-991.
43. Schutte BC, et al. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA 2002;99:2129-2133.
44. Scheetz T, Bartlett JA, Walters JD, Schutte BC, Casavant TL, McCray PB Jr. Genomics-based approaches to gene discovery in innate immunity. Immunol Rev 2002;190:137-145.
45. Rodriguez-Jimenez FJ, et al. Distribution of new human beta-defensin genes clustered on chromosome 20 in functionally different segments of epididymis. Genomics 2003;81:175-183.
46. Jia HP, et al. Discovery of new human beta-defensins using a genomics-based approach. Gene 2001;263:211-218.
47. Das S, et al. Comparative genomics and evolution of the alpha-defensin multigene family in primates. Mol Biol Evol 2010;27:2333-2343.
48. Huttner KM, Selsted ME, Ouellette AJ. Structure and diversity of the murine cryptdin gene family. Genomics 1994;19:448-453.
49. Mastroianni JR, Ouellette AJ. Alpha-defensins in enteric innate immunity: functional Paneth cell alpha-defensins in mouse colonic lumen. J Biol Chem 2009;284:27848-27856.
50. Selsted ME, Miller SI, Henschen AH, Ouellette AJ. Enteric defensins: antibiotic peptide components of intestinal host defense. J Cell Biol 1992;118:929-936.
51. Shanahan MT, Tanabe H, Ouellette AJ. Strain-specific polymorphisms in Paneth cell alpha-defensins of C57BL/6 mice and evidence of vestigial myeloid alpha-defensin pseudogenes. Infect Immun 2011;79:459-473.
52. Bruhn O, Paul S, Tetens J, Thaller G. The repertoire of equine intestinal alpha-defensins. BMC Genomics 2009;10:631.
53. Couto MA, Harwig SS, Cullor JS, Hughes JP, Lehrer RI. Identification of eNAP-1, an antimicrobial peptide from equine neutrophils. Infect Immun 1992;60:3065-3071.
54. Eisenhauer PB, Lehrer RI. Mouse neutrophils lack defensins. Infect Immun 1992;60:3446-3447.
55. Daly NL, et al. Retrocyclin-2: structural analysis of a potent anti-HIV theta-defensin. Biochemistry 2007;46:9920-9928.
56. Trabi M, Schirra HJ, Craik DJ. Three-dimensional structure of RTD-1, a cyclic antimicrobial defensin from Rhesus macaque leukocytes. Biochemistry 2001;40:4211-4221.
57. Leonova L, et al. Circular minidefensins and posttranslational generation of molecular diversity. J Leukoc Biol 2001;70:461-464.
58. Selsted ME. Theta-defensins: cyclic antimicrobial peptides produced by binary ligation of truncated alpha-defensins. Curr Protein Pept Sci 2004;5:365-371.
59. Nguyen TX, Cole AM, Lehrer RI. Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides 2003;24:1647-1654.
60. Gallo SA, et al. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006;281:18787-18792.
61. Wohlford-Lenane CL, et al. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol 2009;83:11385-11390.
62. Yasin B, et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 2004;78:5147-5156.
63. Cole AM, et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002;99:1813-1818.
64. Arnett E, Lehrer RI, Pratikhya P, Lu W, Seveau S. Defensins enable macrophages to inhibit the intracellular proliferation of Listeria monocytogenes. Cell Microbiol 2011;13:635-651.
65. Welkos S, et al. Humanized {theta}-defensins (retrocyclins) enhance macrophage performance and protect mice from experimental anthrax infections. Antimicrob Agents Chemother 2011;55:4238-4250.
66. Tongaonkar P, et al. Rhesus macaque theta-defensin isoforms: expression, antimicrobial activities, and demonstration of a prominent role in neutrophil granule microbicidal activities. J Leukoc Biol 2011;89:283-290.
67. Garcia AE, Osapay G, Tran PA, Yuan J, Selsted ME. Isolation, synthesis, and antimicrobial activities of naturally occurring theta-defensin isoforms from baboon leukocytes. Infect Immun 2008;76:5883-5891.
68. Tran D, et al. Microbicidal properties and cytocidal selectivity of rhesus macaque theta defensins. Antimicrob Agents Chemother 2008;52:944-953.
69. Venkataraman N, et al. Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol 2009;7:e95.
70. Penberthy WT, Chari S, Cole AL, Cole AM. Retrocyclins and their activity against HIV-1. Cell Mol Life Sci 2011;68:2231-2242.
71. Hoover DM, Chertov O, Lubkowski J. The structure of human beta-defensin-1: new insights into structural properties of beta-defensins. J Biol Chem 2001;276:39021-39026.
72. Hoover DM, et al. The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem 2000;275:32911-32918.
73. Wu Z, et al. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci USA 2003;100:8880-8885.
74. Hoover DM, et al. The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem 2002;277:37647-37654.
75. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. Cell Mol Life Sci 2006;63:1294-1313.
76. Zou G, et al. Toward understanding the cationicity of defensins. Arg and Lys versus their noncoded analogs. J Biol Chem 2007;282:19653-19665.
77. Lin YZ, Ke XH, Tam JP. Synthesis and structure-activity study of myxoma virus growth factor. Biochemistry 1991;30:3310-3314.
78. Tam JP, Wu C-R, Liu W, Zhang JW. Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications. J Am Chem Soc 1991;113:6657-6662.
79. Mandal M, Nagaraj R. Antibacterial activities and conformations of synthetic alpha-defensin HNP-1 and analogs with one, two and three disulfide bridges. J Pept Res 2002;59:95-104.
80. Raj PA, Antonyraj KJ, Karunakaran T. Large-scale synthesis and functional elements for the antimicrobial activity of defensins. Biochem J 2000;347:633-641.
81. Wu Z, Powell R, Lu W. Productive folding of human neutrophil alpha-defensins in vitro without the pro-peptide. J Am Chem Soc 2003;125:2402-2403.
82. Szyk A, Wu Z, Tucker K, Yang D, Lu W, Lubkowski J. Crystal structures of human alpha-defensins HNP4, HD5, and HD6. Protein Sci 2006;15:2749-2760.
83. Pazgier M, Li X, Lu W, Lubkowski J. Human defensins: synthesis and structural properties. Curr Pharm Des 2007;13:3096-3118.
84. Louria DB, Brayton RG. A substance in blood lethal for Candida albicans. Nature 1964;201:309.
85. Louria DB, Smith JK, Brayton RG, Buse M. Anti-Candida factors in serum and their inhibitors. I. Clinical and laboratory observations. J Infect Dis 1972;125:102-114.
86. Lehrer RI, Cline MJ. Interaction of Candida albicans with human leukocytes and serum. J Bacteriol 1969;98:996-1004.
87. Chilgren RA, Hong R, Quie PG. Human serum interactions with Candida albicans. J Immunol 1968;101:128-132.
88. Ashman RB, Fara CS. Oral candidiasis: clinical manifestations and cellular adaptive host responses. In: Fidel PM, Huffnagle GB eds. Fungal Immunology: From an Organ Perspective. New York: Springer, 2005:60-83.
89. Gottlieb MS. Pneumocystis pneumonia - Los Angeles. 1981. Am J Public Health 2006;96:980-981.
90. deSouza W, Benchimol M. Basic biology of Pneumocystis carinii: a mini review. Mem Inst Oswaldo Cruz 2005;100:903-908.
91. Joffrion TM, Cushion MT. Sterol biosynthesis and sterol uptake in the fungal pathogen Pneumocystis carinii. FEMS Microbiol Lett 2010;311:1-9.
92. Glittenberg MT, et al. Pathogen and host factors are needed to provoke a systemic host response to gastrointestinal infection of Drosophila larvae by Candida albicans. Dis Model Mech 2011;4:515-525.
93. Koh AY, Kohler JR, Coggshall KT, Van RN, Pier GB. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 2008;4:e35.
94. Fraser CG. The action of methylene-blue and certain other dyes on living and dead yeast. J Phys Chem 1920;24:741-748.
95. Metschnikoff E. Sur la lutte des cellules de l'organisme contre l'invasion des microbes. Ann Inst Pasteur 1887;1:321-336.
96. Knaysi G. A microscopic method of distinguishing dead from living bacterial cells. J Bacteriol 1935;30:193-206.
97. Lehrer RI. The fungicidal mechanisms of human monocytes. I. Evidence for myeloperoxidase-linked and myeloperoxidase-independent candidacidal mechanisms. J Clin Invest 1975;55:338-346.
98. Lehrer RI, Cline MJ. Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest 1969;48:1478-1488.
99. Lehrer RI, Hanifin J, Cline MJ. Defective bactericidal activity in myeloperoxidase-deficient human neutrophils. Nature 1969;223:78-79.
100. Salmon SE, Cline MJ, Schultz J, Lehrer RI. Myeloperoxidase deficiency. Immunologic study of a genetic leukocyte defect. N Engl J Med 1970;282:250-253.
101. Marchetti C, Patriarca P, Solero GP, Baralle F, Romano M. Genetic characterization of myeloperoxidase deficiency in Italy. Hum Mutat 2004;23:496-505.
102. Nunoi H, Kohi F, Kajiwara H, Suzuki K. Prevalence of inherited myeloperoxidase deficiency in Japan. Microbiol Immunol 2003;47:527-531.
103. Brennan ML, et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 2001;107:419-430.
104. Eisenhauer P, Harwig SS, Szklarek D, Ganz T, Lehrer RI. Polymorphic expression of defensins in neutrophils from outbred rats. Infect Immun 1990;58:3899-3902.
105. Eisenhauer PB, Harwig SS, Szklarek D, Ganz T, Selsted ME, Lehrer RI. Purification and antimicrobial properties of three defensins from rat neutrophils. Infect Immun 1989;57:2021-2027.
106. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625.
107. Rice WG, Ganz T, Kinkade JM, Selsted ME, Lehrer RI, Parmley RT. Defensin-rich dense granules of human neutrophils. Blood 1987;70:757-765.
108. Wilde CG, Snable JL, Griffith JE, Scott RW. Characterization of two azurphil granule proteases with active-site homology to neutrophil elastase. J Biol Chem 1990;265:2038-2041.
109. Brune K, Leffell MS, Spitznagel JK. Microbicidal activity of peroxidaseless chicken heterophile leukocytes. Infect Immun 1972;5:283-287.
110. Brune K, Spitznagel JK. Peroxidaseless chicken leukocytes: isolation and characterization of antibacterial granules. J Infect Dis 1973;127:84-94.
111. Harwig SS, et al. Gallinacins: cysteine-rich antimicrobial peptides of chicken leukocytes. FEBS Lett 1994;342:281-285.
112. Hohn DC, Lehrer RI. NADPH oxidase deficiency in X-linked chronic granulomatous disease. J Clin Invest 1975;55:707-713.
113. Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 2010;68:334-340.
114. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010;38:3-10.
115. Foote CS, Goyne T, Lehrer RI. Assessment of chlorination by human neutrophils. Nature 1983;301:715-716.
116. Klebanoff SJ. Iodination of bacteria: a bactericidal mechanism. J Exp Med 1967;126:1063-1078.
117. Lehrer RI. Measurement of candidacidal activity of specific leukocyte types in mixed cell populations II. Normal and chronic granulomatous disease eosinophils. Infect Immun 1971;3:800-802.
118. Babior BM, Curnutte JT, McMurrich BJ. The particulate superoxide-forming system from human neutrophils. Properties of the system and further evidence supporting its participation in the respiratory burst. J Clin Invest 1976;58:989-996.
119. Baehner RL, Nathan DG. Leukocyte oxidase: defective activity in chronic granulomatous disease. Science 1967;155:835-836.
120. Holmes B, Page AR, Good RA. Studies of the metabolic activity of leukocytes from patients with a genetic abnormality of phagocytic function. J Clin Invest 1967;46:1422-1432.
121. Klebanoff SJ, Pincus SH. Hydrogen peroxide utilization in myeloperoxidase-deficient leukocytes: a possible microbicidal control mechanism. J Clin Invest 1971;50:2226-2229.
122. Klebanoff SJ. Myeloperoxidase-halide-hydrogen peroxide antibacterial system. J Bacteriol 1968;95:2131-2138.
123. Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proc R Soc B 1922;93:306-331.
124. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Brit J Exp Path 1929;10:226-236.
125. Fleming A. President's address. Proc R Soc Med 1932;26:71-84.
126. Cruickshank R. Obituary. Alexander Fleming. J Pathol Bacteriol 1955;72:697-708.
127. Seibold M, Wolschann P, Bodevin S, Olsen O. Properties of the bubble protein, a defensin and an abundant component of a fungal exudate. Peptides 2011;32:1989-1995.
128. Hirsch JG. Studies of the bactericidal action of phagocytin. J Exp Med 1956;103:613-621.
129. Hirsch JG. Phagocytin: a bactericidal substance from polymorphonuclear leucocytes. J Exp Med 1956;103:589-611.
130. Cohn ZA, Hirsch JG. The influence of phagocytosis on the intracellular distribution of granule-associated components of polymorphonuclear leucocytes. J Exp Med 1960;112:1015-1022.
131. Cohn ZA, Hirsch JG. The isolation and properties of the specific cytoplasmic granules of rabbit polymorphonuclear leucocytes. J Exp Med 1960;112:983-1004.
132. Hirsch JG. Further studies on preparation and properties of phagocytin. J Exp Med 1960;111:323-337.
133. Hirsch JG, Cohn ZA. Degranulation of polymorphonuclear leucocytes following phagocytosis of microorganisms. J Exp Med 1960;112:1005-1014.
134. Spitznagel JK. The effects of mammalian and other cationic polypeptides on the cytochemical character of bacterial cells. J Exp Med 1961;114:1063-1078.
135. Spitznagel JK. Antibacterial effects associated with changes in bacterial cytology produced by cationic polypeptides. J Exp Med 1961;114:1079-1091.
136. Spitznagel JK, Chi HY. Cationic proteins and antibacterial properties of infected tissues and leukocytes. Am J Pathol 1963;43:697-711.
137. Spitznagel JK, Zeya HI. Basic proteins and leukocyte lysosomes as biochemical determinants of resistance to infection. Trans Assoc Am Physicians 1964;77:126-134.
138. Spitznagel JK, et al. Character of azurophil and specific granules purified from human polymorphonuclear leukocytes. Lab Invest 1974;30:774-785.
139. Spitznagel JK. Nonoxidative antimicrobial reactions of leukocytes. Contemp Top Immunobiol 1984;14:283-343.
140. Lehrer RI. Functional aspects of a second mechanism of candidacidal activity by human neutrophils. J Clin Invest 1972;51:2566-2572.
141. Lehrer RI, Ladra KM, Hake RB. Nonoxidative fungicidal mechanisms of mammalian granulocytes: demonstration of components with candidacidal activity in human, rabbit, and guinea pig leukocytes. Infect Immun 1975;11:1226-1234.
142. Lehrer RI, Ladra KM. Fungicidal components of mammalian granulocytes active against Cryptococcus neoformans. J Infect Dis 1977;136:96-99.
143. Drazin RE, Lehrer RI. Fungicidal properties of a chymotrypsin-like cationic protein from human neutrophils: adsorption to Candida parapsilosis. Infect Immun 1977;17:382-388.
144. Meyer-Hoffert U, Wiedow O. Neutrophil serine proteases: mediators of innate immune responses. Curr Opin Hematol 2011;18:19-24.
145. Burster T, Macmillan H, Hou T, Boehm BO, Mellins ED. Cathepsin G: roles in antigen presentation and beyond. Mol Immunol 2010;47:658-665.
146. Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 2008;90:227-242.
147. Shafer WM, et al. Tailoring an antibacterial peptide of human lysosomal cathepsin G to enhance its broad-spectrum action against antibiotic-resistant bacterial pathogens. Curr Pharm Des 2002;8:695-702.
148. Egesten A, Breton-Gorius J, Guichard J, Gullberg U, Olsson I. The heterogeneity of azurophil granules in neutrophil promyelocytes: immunogold localization of myeloperoxidase, cathepsin G, elastase, proteinase 3, and bactericidal/permeability increasing protein. Blood 1994;83:2985-2994.
149. Gabay JE. Antimicrobial proteins with homology to serine proteases. Ciba Found Symp 1994;186:237-247.
150. Brandt K, Lundell K, Brismar K. Neutrophil-derived azurocidin cleaves insulin-like growth factor-binding protein-1, -2 and -4. Growth Horm IGF Res 2011;21:167-173.
151. Linder A, Soehnlein O, Akesson P. Roles of heparin-binding protein in bacterial infections. J Innate Immun 2010;2:431-438.
152. Gabay JE, et al. Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1989;86:5610-5614.
153. Odeberg H, Olsson I. Microbicidal mechanisms of human granulocytes: synergistic effects of granulocyte elastase and myeloperoxidase or chymotrypsin-like cationic protein. Infect Immun 1976;14:1276-1283.
154. Garcia R, Gusmani L, Murgia R, Guarnaccia C, Cinco M, Rottini G. Elastase is the only human neutrophil granule protein that alone is responsible for in vitro killing of Borrelia burgdorferi. Infect Immun 1998;66:1408-1412.
155. Sorensen O, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001;97:3951-3959.
156. Larrick JW, et al. Structural, functional analysis and localization of the human CAP18 gene. FEBS Lett 1996;398:74-80.
157. Lehrer RI, Ganz T. Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol 2002;9:18-22.
158. Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol 2009;16:41-47.
159. Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R. Cathelicidin peptides as candidates for a novel class of antimicrobials. Curr Pharm Des 2002;8:779-793.
160. Wang-Iverson P, Pryzwansky KB, Spitznagel JK, Cooney MH. Bactericidal capacity of phorbol myristate acetate-treated human polymorphonuclear leukocytes. Infect Immun 1978;22:945-955.
161. Patterson-Delafield J, Martinez RJ, Lehrer RI. Microbicidal cationic proteins in rabbit alveolar macrophages: a potential host defense mechanism. Infect Immun 1980;30:180-192.
162. Patterson-Delafield J, Szklarek D, Martinez RJ, Lehrer RI. Microbicidal cationic proteins of rabbit alveolar macrophages: amino acid composition and functional attributes. Infect Immun 1981;31:723-731.
163. Lehrer RI, Daher K, Ganz T, Selsted ME. Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. J Virol 1985;54:467-472.
164. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol 1986;60:1068-1074.
165. Harwig SS, Park AS, Lehrer RI. Characterization of defensin precursors in mature human neutrophils. Blood 1992;79:1532-1537.
166. Wang W, Cole AM, Hong T, Waring AJ, Lehrer RI. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 2003;170:4708-4716.
167. Lehrer RI, Jung G, Ruchala P, Andre S, Gabius HJ, Lu W. Multivalent binding of carbohydrates by the human alpha-defensin, HD5. J Immunol 2009;183:480-490.
168. Hirsch JG. Bactericidal action of histone. J Exp Med 1956;108:925-944.
169. Myrvik Q, Leake ES, Fariss B. Studies on pulmonary alveolar macrophages from the normal rabbit: a technique to procure them in a high state of purity. J Immunol 1961;86:128-132.
170. Patterson-Delafield J, Lehrer RI. Preparation of rabbit alveolar macrophages in high purity and yield. J Immunol Methods 1980;38:291-294.
171. Fjell CD, et al. Identification of novel host defense peptides and the absence of alpha-defensins in the bovine genome. Proteins 2008;73:420-430.
172. Pope A. An essay on man. In: Cary HF ed. Poetical Works. London: Routledge, 1870:225-226.
173. Ouellette AJ, et al. Mouse Paneth cell defensins: primary structures and antibacterial activities of numerous cryptdin isoforms. Infect Immunol 1994;62:5040-5047.
174. Belcourt D, Singh A, Bateman A, Lazure C, Solomon S, Bennett HP. Purification of cationic cystine-rich peptides from rat bone marrow. Primary structures and biological activity of the rat corticostatin family of peptides. Regul Pept 1992;40:87-100.
175. Yamamoto CM, Banaiee N, Yount NY, Patel B, Selsted ME. Alpha-defensin expression during myelopoiesis: identification of cis and trans elements that regulate expression of NP-3 in rat promyelocytes. J Leukoc Biol 2004;75:332-341.
176. Yount NY, Wang MS, Yuan J, Banaiee N, Ouellette AJ, Selsted ME. Rat neutrophil defensins. Precursor structures and expression during neutrophilic myelopoiesis. J Immunol 1995;155:4476-4484.
177. Aldred PM, Hollox EJ, Armour JA. Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005;14:2045-2052.
178. Linzmeier RM, Ganz T. Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics 2005;86:423-430.
179. Linzmeier RM, Ganz T. Copy number polymorphisms are not a common feature of innate immune genes. Genomics 2006;88:122-126.
180. Wehkamp J, Stange EF, Fellermann K. Defensin-immunology in inflammatory bowel disease. Gastroenterol Clin Biol 2009;33(Suppl):S137-S144.
181. Hollox EJ. Copy number variation of beta-defensins and relevance to disease. Cytogenet Genome Res 2008;123:148-155.
182. Hollox EJ, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23-25.
183. Janssens W, et al. Genomic copy number determines functional expression of {beta}-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:163-169.
184. Fode P, et al. Determination of beta-defensin genomic copy number in different populations: a comparison of three methods. PLoS ONE 2011;6:e16768.
185. Jespersgaard C, et al. Alpha-defensin DEFA1A3 gene copy number elevation in Danish Crohn's disease patients. Dig Dis Sci 2011, doi:.
186. Dale DC, Liles WC, Llewellyn C, Price TH. Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. Am J Hematol 1998;57:7-15.
187. Ganz T. Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun 1987;55:568-571.
188. Lominadze G, Powell DW, Luerman GC, Link AJ, Ward RA, McLeish KR. Proteomic analysis of human neutrophil granules. Mol Cell Proteomics 2005;4:1503-1521.
189. Sengelov H, Follin P, Kjeldsen L, Lollike K, Dahlgren C, Borregaard N. Mobilization of granules and secretory vesicles during in vivo exudation of human neutrophils. J Immunol 1995;154:4157-4165.
190. Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994;83:799-807.
191. Uriarte SM, et al. Comparison of proteins expressed on secretory vesicle membranes and plasma membranes of human neutrophils. J Immunol 2008;180:5575-5581.
192. Urban CF, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 2009;5:e1000639.
193. Sohnle PG, Collins-Lech C. Comparison of candidacidal and candidastatic activities of human neutrophils. Infect Immun 1990;58:2696-2698.
194. Sohnle PG, Collins-Lech C, Wiessner JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J Infect Dis 1991;164:137-142.
195. McNamara MP, Wiessner JH, Collins-Lech C, Hahn BL, Sohnle PG. Neutrophil death as a defence mechanism against Candida albicans infections. Lancet 1988;2:1163-1165.
196. Donini M, et al. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. Blood 2007;109:4716-4723.
197. Putsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002;360:1144-1149.
198. Palfree RG, Sadro LC, Solomon S. The gene encoding the human corticostatin HP-4 precursor contains a recent 86-base duplication and is located on chromosome 8. Mol Endocrinol 1993;7:199-205.
199. Zhu QZ, Singh AV, Bateman A, Esch F, Solomon S. The corticostatic (anti-ACTH) and cytotoxic activity of peptides isolated from fetal, adult and tumor-bearing lung. J Steroid Biochem 1987;27:1017-1022.
200. Zhu QZ, Hu J, Mulay S, Esch F, Shimasaki S, Solomon S. Isolation and structure of corticostatin peptides from rabbit fetal and adult lung. Proc Natl Acad Sci USA 1988;85:592-596.
201. Zhu Q, Bateman A, Singh A, Solomon S. Isolation and biological activity of corticostatic peptides (anti-ACTH). Endocr Res 1989;15:129-149.
202. Zhu Q, Solomon S. Isolation and mode of action of rabbit corticostatic (antiadrenocorticotropin) peptides. Endocrinology 1992;130:1413-1423.
203. Solomon S, et al. Corticostatic peptides. J Steroid Biochem Mol Biol 1991;40:391-398.
204. Solomon S. Corticostatins. Trends Endocrinol Metab 1993;4:260-264.
205. Clarke BL, Bost KL. Differential expression of functional adrenocorticotropic hormone receptors by subpopulations of lymphocytes. J Immunol 1989;143:464-469.
206. Johnson EW, Hughes TK Jr, Smith EM. ACTH receptor distribution and modulation among murine mononuclear leukocyte populations. J Biol Regul Homeost Agents 2001;15:156-162.
207. Blalock JE. Proopiomelanocortin and the immune-neuroendocrine connection. Ann NY Acad Sci 1999;885:161-172.
208. Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human {alpha}-defensins. Antimicrob Agents Chemother 2005;49:269-275.
209. Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989;84:2017-2020.
210. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw 2000;11:257-266.
211. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000;68:9-14.
212. Lillard JW Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci USA 1999;96:651-656.
213. Yang D, Chertov O, Oppenheim JJ. Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J Leukoc Biol 2001;69:691-697.
214. Rohrl J, Yang D, Oppenheim JJ, Hehlgans T. Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol 2010;184:6688-6694.
215. Grigat J, Soruri A, Forssmann U, Riggert J, Zwirner J. Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human alpha-defensin family. J Immunol 2007;179:3958-3965.
216. Lehrer RI. Primate defensins. Nat Rev Microbiol 2004;2:727-738.
217. Leikina E, et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005;6:995-1001.
218. Wang W, et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004;173:515-520.
219. Borenstein LA, Ganz T, Sell S, Lehrer RI, Miller JN. Contribution of rabbit leukocyte defensins to the host response in experimental syphilis. Infect Immun 1991;59:1368-1377.
220. Borenstein LA, Selsted ME, Lehrer RI, Miller JN. Antimicrobial activity of rabbit leukocyte defensins against Treponema pallidum subsp. pallidum. Infect Immun 1991;59:1359-1367.
221. Hill CP, Yee J, Selsted ME, Eisenberg D. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 1991;251:1481-1485.
222. Zhang XL, Selsted ME, Pardi A. NMR studies of defensin antimicrobial peptides. 1. Resonance assignment and secondary structure determination of rabbit NP-2 and human HNP-1. Biochemistry 1992;31:11348-11356.
223. Pardi A, Zhang XL, Selsted ME, Skalicky JJ, Yip PF. NMR studies of defensin antimicrobial peptides. 2. Three-dimensional structures of rabbit NP-2 and human HNP-1. Biochemistry 1992;31:11357-11364.
224. Wei G, et al. Trp-26 imparts functional versatility to human alpha-defensin HNP1. J Biol Chem 2010;285:16275-16285.
225. Xie C, et al. Reconstruction of the conserved beta-bulge in mammalian defensins using D-amino acids. J Biol Chem 2005;280:32921-32929.
226. Zhang Y, Lu W, Hong M. The membrane-bound structure and topology of a human alpha-defensin indicate a dimer pore mechanism for membrane disruption. Biochemistry 2010;49:9770-9782.
227. Zhang Y, et al. Resonance assignment and three-dimensional structure determination of a human alpha-defensin, HNP-1, by solid-state NMR. J Mol Biol 2010;397:408-422.
228. Wimley WC, Selsted ME, White SH. Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci 1994;3:1362-1373.
229. Lehrer RI, et al. Human alpha-defensins inhibit hemolysis mediated by cholesterol-dependent cytolysins. Infect Immun 2009;77:4028-4040.
230. Ghosh D, et al. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 2002;3:583-590.
231. Valore EV, Ganz T. Posttranslational processing of defensins in immature human myeloid cells. Blood 1992;79:1538-1544.
232. Maemoto A, et al. Functional analysis of the alpha-defensin disulfide array in mouse cryptdin-4. J Biol Chem 2004;279:44188-44196.
233. Tanabe H, et al. Denatured human alpha-defensin attenuates the bactericidal activity and the stability against enzymatic digestion. Biochem Biophys Res Commun 2007;358:349-355.
234. Kim C, et al. Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc Natl Acad Sci USA 2005;102:4830-4835.
235. Wei G, et al. Through the looking glass, mechanistic insights from enantiomeric human defensins. J Biol Chem 2009;284:29180-29192.
236. deLeeuw E, et al. Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. FEBS Lett 2010;584:1543-1548.
237. Miles K, et al. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of alpha-defensins. J Immunol 2009;183:2122-2132.
238. deLeeuw E, Burks SR, Li X, Kao JP, Lu W. Structure-dependent functional properties of human defensin 5. FEBS Lett 2007;581:515-520.
239. Smith JG, Silvestry M, Lindert S, Lu W, Nemerow GR, Stewart PL. Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog 2010;6:e1000959.
240. Wu Z, et al. Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro. FEBS Lett 2005;579:162-166.
241. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol 2006;6:447-456.
242. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 2007;109:2928-2935.
243. Klotman ME, et al. Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol 2008;180:6176-6185.
244. Rapista A, et al. Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology 2011;8:45.
245. Varkey J, Nagaraj R. Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines. Antimicrob Agents Chemother 2005;49:4561-4566.
246. Wanniarachchi YA, Kaczmarek P, Wan A, Nolan EM. Human defensin 5 disulfide array mutants: disulfide bond deletion attenuates antibacterial activity against Staphylococcus aureus. Biochemistry 2011;50:8005-8017.
247. Kluver E, Schulz-Maronde S, Scheid S, Meyer B, Forssmann WG, Adermann K. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 2005;44:9804-9816.
248. Lehrer RI. Immunology: peptide gets in shape for self-defence. Nature 2011;469:309-310.
249. Schroeder BO, et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1. Nature 2011;469:419-423.
250. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 1989;84:553-561.
251. Katchalski E, Bichowski-Slomnitzki L, Volcani BE. The action of some water-soluble poly-alpha-amino acids on bacteria. Biochem J 1953;55:671-680.
252. Buchanan-Davidson DJ, Seastone CV, Stahmann MA. Action of synthetic polylysine on the growth and phagocytosis of bacteria in vitro. J Bacteriol 1960;80:590-594.
253. Aspedon A, Groisman EA. The antibacterial action of protamine: evidence for disruption of cytoplasmic membrane energization in Salmonella typhimurium. Microbiology 1996;142:3389-3397.
254. Gadebusch HH, Johnson AG. Natural host resistance to infection with Cryptococcus neoformans. IV. The effect of some cationic proteins on the experimental disease. J Infect Dis 1966;116:551-565.
255. Miller BF, Abrams R, Dorfman A, Klein M. Antibacterial properties of protamines and histones. Science 1942;96:428-430.
256. Hiemstra PS, Eisenhauer PB, Harwig S, van den Barselaar MT, vanFurth R, Lehrer RI. Antimicrobial proteins of murine macrophages. Infect Immun 1993;61:3038-3046.
257. Rose FR, Bailey K, Keyte JW, Chan WC, Greenwood D, Mahida YR. Potential role of epithelial cell-derived histone H1 proteins in innate antimicrobial defense in the human gastrointestinal tract. Infect Immun 1998;66:3255-3263.
258. Tollin M, Bergman P, Svenberg T, Jornvall H, Gudmundsson GH, Agerberth B. Antimicrobial peptides in the first line defence of human colon mucosa. Peptides 2003;24:523-530.
259. Wu ER, Daniel R, Bateman A. RK-2: a novel rabbit kidney defensin and its implications for renal host defense. Peptides 1998;19:793-799.
260. Bateman A, MacLeod RJ, Lembessis P, Hu J, Esch F, Solomon S. The isolation and characterization of a novel corticostatin/defensin-like peptide from the kidney. J Biol Chem 1996;271:10654-10659.
261. Nagaoka I, Someya A, Iwabuchi K, Yamashita T. Characterization of cDNA clones encoding guinea pig neutrophil cationic peptides. FEBS Lett 1991;280:287-291.
262. Selsted ME, Harwig SS. Purification, primary structure, and antimicrobial activities of a guinea pig neutrophil defensin. Infect Immun 1987;55:2281-2286.
263. Rajabi M, deLeuuw E, Pazgier M, Li J, Lubkowski J, Lu W. The conserved salt-bridge in human alpha-defensin 5 is required for its precursor processing and proteolytic stability. J. Biol Chem 2008;283:21509-21518.
264. Wu Z, Li X, deLeeuw E, Ericksen B, Lu W. Why is the Arg5-Glu13 salt-bridge conserved in mammalian alpha-defensins? J. Biol Chem 2005;280:43039-43047.
265. Wu Z, et al. Impact of pro segments on the folding and function of human neutrophil alpha-defensins. J Mol Biol 2007;368:537-549.
266. Zou G, deLeeuw E, Lubkowski J, Lu W. Molecular determinants for the interaction of human neutrophil alpha defensin 1 with its propeptide. J Mol Biol 2008;381:1281-1291.
267. Faurschou M, et al. Prodefensins are matrix proteins of specific granules in human neutrophils. J Leuk Biol 2005;78:785-793.
268. Liu L, Ganz T. The pro region of human neutrophil defensin contains a motif that is essential for normal subcellular sorting. Blood 1995;85:1095-1103.
269. Michaelson D, Rayner J, Couto M, Ganz T. Cationic defensins arise from charge-neutralized propeptides: a mechanism for avoiding leukocyte autocytotoxicity? J Leukoc Biol 1992;51:634-639.
270. Rosengren KJ, et al. Structural and functional characterization of the conserved salt-bridge in mammalian paneth cell alpha-defensins: solution structures of mouse Cryptdin-4 and (E15D)-Cryptdin-4. J Biol Chem 2006;281:28068-28078.
271. Yount NY, Yeaman MR. Multidimensional signatures in antimicrobial peptides. Proc Natl Acad Sci USA 2004;101:7363-7368.
272. Richardson JS, Getzoff ED, Richardson DC. The beta bulge: a common small unit of nonrepetitive protein structure. Proc Natl Acad Sci USA 1978;75:2574-2578.
273. Chan AW, Hutchinson EG, Harris D, Thornton JM. Identification, classification, and analysis of beta-bulges in proteins. Protein Sci 1993;2:1574-1590.
274. Xie C, Zeng P, Ericksen B, Wu Z, Lu WY, Lu W. Effects of the terminal charges in human neutrophil alpha-defensin 2 on its bactericidal and membrane activity. Peptides 2005;26:2377-2383.
275. Buck CB, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci USA 2006;103:1516-1521.
276. deLeeuw E, Rajabi M, Zou G, Pazgier M, Lu W. Selective arginines are important for the antibacterial activity and host cell interaction of human alpha-defensin 5. FEBS Lett 2009;583:2507-2512.
277. Figueredo SM, Weeks CS, Young SK, Ouellette AJ. Anionic amino acids near the pro-alpha-defensin N terminus mediate inhibition of bactericidal activity in mouse pro-cryptdin-4. J Biol Chem 2009;284:6826-6831.
278. Llenado RA, Weeks CS, Cocco MJ, Ouellette AJ. Electropositive charge in alpha-defensin bactericidal activity: functional effects of Lys-for-Arg substitutions vary with the peptide primary structure. Infect Immun 2009;77:5035-5043.
279. Stevens LA, Levine RL, Gochuico BR, Moss J. ADP-ribosylation of huma defensin HNP-1 results in the replacement of the modified arginine with the nocoded amino acid ornithine. Proc Natl Acad Sci USA 2009;106:19796-19800.
280. Balducci E, Bonucci A, Picchianti M, Pogni R, Talluri E. Structural and funfctional consequences induced by post-translational modifications in α-defensins. Int J Pept 2011; doi:.
281. Paone G, et al. ADP ribosylation of human neutrophil peptide-1 regulates its biological properties. Proc Natl Acad Sci USA 2002;99:8231-8235.
282. Valore EV, Martin E, Harwig SS, Ganz T. Intramolecular inhibition of human defensin HNP-1 by its propiece. J Clin Invest 1996;97:1624-1629.
283. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005;3:238-250.
284. Kagan BL, Selsted ME, Ganz T, Lehrer RI. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci USA 1990;87:210-214.
285. Kouno T, et al. A novel beta-defensin structure: a potential strategy of big defensin for overcoming resistance by Gram-positive bacteria. Biochemistry 2008;47:10611-10619.
286. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H, de Kruijff B. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 1999;286:2361-2364.
287. Breukink E, de Kruijff B. Lipid II as a target for antibiotics. Nat Rev Drug Discov 2006;5:321-332.
288. Hasper HE, et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 2006;313:1636-1637.
289. Bierbaum G, Sahl HG. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol 2009;10:2-18.
290. Sass V, et al. Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect Immun 2010;78:2793-2800.
291. Schmitt P, et al. Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J Biol Chem 2010;285:29208-29216.
292. Schneider T, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 2010;328:1168-1172.
293. Cech P, Lehrer RI. Phagolysosomal pH of human neutrophils. Blood 1984;63:88-95.
294. Lloyd-Evans E, Waller-Evans H, Peterneva K, Platt FM. Endolysosomal calcium regulation and disease. Biochem Soc Trans 2010;38:1458-1464.
295. Panyutich AV, Panyutich EA, Krapivin VA, Baturevich EA, Ganz T. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J Lab Clin Med 1993;122:202-207.
296. McKay MS, et al. Immunomagnetic recovery of human neutrophil defensins from the human gingival crevice. Oral Microbiol Immunol 1999;14:190-193.
297. Tonetti MS. Molecular factors associated with compartmentalization of gingival immune responses and transepithelial neutrophil migration. J Periodontal Res 1997;32:104-109.
298. Clark RA, Page RC, Wilde G. Defective neutrophil chemotaxis in juvenile periodontitis. Infect Immun 1977;18:694-700.
299. Selsted ME, Szklarek D, Ganz T, Lehrer RI. Activity of rabbit leukocyte peptides against Candida albicans. Infect Immun 1985;49:202-206.
300. Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P. Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 1991;137:167-173.
301. Jimenez-Barbero J, Bouffar-Roupe C, Rochas C, Perez S. Modelling studies of solvent effects on the conformational stability of agarobiose and neoagarobiose and their relationship to agarose. Int J Biol Macromol 1989;11:265-272.
302. Arnljots K, Sorensen O, Lollike K, Borregaard N. Timing, targeting and sorting of azurophil granule proteins in human myeloid cells. Leukemia 1998;12:1789-1795.
303. Agerberth B, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000;96:3086-3093.
304. Riepl B, Grassel S, Wiest R, Fleck M, Straub RH. Tumor necrosis factor and norepinephrine lower the levels of human neutrophil peptides 1-3 secretion by mixed synovial tissue cultures in osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2010;12:R110.
305. Morel E, et al. Expression of alpha-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions. Allergy 2011;66:360-367.
306. Hazrati E, et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006;177:8658-8666.
307. Tan BH, et al. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol 2006;177:1864-1871.
308. Cohn ZA, Parks E. The regulation of pinocytosis in mouse macrophages. II. Factors inducing vesicle formation. J Exp Med 1967;125:213-232.
309. Burnett RJ, Lyden CA, Tindal CJ, Cave CM, Marra MN, Solomkin JS. Mononuclear cell line THP-1 internalizes bactericidal/permeability-increasing protein by a non-receptor-mediated mechanism consistent with pinocytosis. Arch Surg 1996;131:200-205.
310. Shafer WM, Pohl J, Onunka VC, Bangalore N, Travis J. Human lysosomal cathepsin G and granzyme B share a functionally conserved broad spectrum antibacterial peptide. J Biol Chem 1991;266:112-116.
311. Cohen J. AIDS research. Mystery anti-HIV factor unmasked? Science 2002;297:2188.
312. Zhang L, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002;298:995-1000.
313. Chang TL, Francois F, Mosoian A, Klotman ME. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J Virol 2003;77:6777-6784.
314. Trabattoni D, et al. Human alpha defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr 2004;35:455-463.
315. Cohen IB. The first English version of Newton's Hypotheses non fingo. ISIS 1962;53:379-388.
316. Chang TL, Vargas J Jr, DelPortillo A, Klotman ME. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005;115:765-773.
317. Porter E, et al. Distinct defensin profiles in Neisseria gonorrhoeae and Chlamydia trachomatis urethritis reveal novel epithelial cell-neutrophil interactions. Infect Immun 2005;73:4823-4833.
318. Roy CR, Mocarski ES. Pathogen subversion of cell-intrinsic innate immunity. Nat Immunol 2007;8:1179-1187.
319. Murphy PM. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2001;2:116-122.
320. Salvatore M, Garcia-Sastre A, Ruchala P, Lehrer RI, Chang T, Klotman ME. Alpha-defensin inhibits influenza virus replication by cell-mediated mechanism(s). J Infect Dis 2007;196:835-843.
321. Kurokawa M, Ochiai H, Nakajima K, Niwayama S. Inhibitory effect of protein kinase C inhibitor on the replication of influenza type A virus. J Gen Virol 1990;71:2149-2155.
322. Reinhardt J, Wolff T. The influenza A virus M1 protein interacts with the cellular receptor of activated C kinase (RACK) 1 and can be phosphorylated by protein kinase C. Vet Microbiol 2000;74:87-100.
323. Root CN, Wills EG, McNair LL, Whittaker GR. Entry of influenza viruses into cells is inhibited by a highly specific protein kinase C inhibitor. J Gen Virol 2000;81:2697-2705.
324. Sieczkarski SB, Brown HA, Whittaker GR. Role of protein kinase C betaII in influenza virus entry via late endosomes. J Virol 2003;77:460-469.
325. Haidari M, Zhang W, Ganjehei L, Ali M, Chen Z. Inhibition of MLC phosphorylation restricts replication of influenza virus - a mechanism of action for anti-influenza agents. PLoS ONE 2011;6:e21444.
326. Charp PA, et al. Inhibition of protein kinase C by defensins, antibiotic peptides from human neutrophils. Biochem Pharmacol 1988;37:951-956.
327. Tecle T, White MR, Gantz D, Crouch EC, Hartshorn KL. Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses. J Immunol 2007;178:8046-8052.
328. Doss M, et al. Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D. J Immunol 2009;182:7878-7887.
329. Ofek I, Sharon N. Lectinophagocytosis: a molecular mechanism of recognition between cell surface sugars and lectins in the phagocytosis of bacteria. Infect Immun 1988;56:539-547.
330. Nguyen EK, Nemerow GR, Smith JG. Direct evidence from single-cell analysis that human α-defensins block adenovirus uncoating to neutralize infection. J Virol 2010;84:4041-4049.
331. Amstutz B, et al. Subversion of CtBP1-controlled macropinocytosis by human adenovirus serotype 3. EMBO J 2008;27:956-969.
332. Kalin S, et al. Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35. J Virol 2010;84:5336-5350.
333. Meier O, et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol 2002;158:1119-1131.
334. Nakano MY, Boucke K, Suomalainen M, Stidwill RP, Greber UF. The first step of adenovirus type 2 disassembly occurs at the cell surface, independently of endocytosis and escape to the cytosol. J Virol 2000;74:7085-7095.
335. Falco A, Mas V, Tafalla A, Perez L, Cott JM, Estepa A. Dual antiviral activity of human alpha-defensin-1 against viral haemorrhagic septicemia rhabdovirus (VHSV): inactivation of virus particles and induction of a type I interferon-related response. Antiviral Res 2007;76:111-123.
336. Ganz T, Liu L, Valore EV, Oren A. Posttranslational processing and targeting of transgenic human defensin in murine granulocyte, macrophage, fibroblast, and pituitary adenoma cell lines. Blood 1993;82:641-650.
337. Liu L, Oren A, Ganz T. Murine 32D c13 cells - a transfectable model of phagocyte granule formation. J Immunol Methods 1995;181:253-258.
338. Knox KS, Hage CA. Histoplasmosis. Proc Am Thorac Soc 2010;7:169-172.
339. Anderson AM, Mehta AK, Wang YF, Jing Q, Easley K, Nguyen ML. HIV-associated histoplasmosis in a nonendemic area of the United States during the HAART era: role of migration from endemic areas and lack of antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic) 2010;9:296-300.
340. Couto MA, Liu L, Lehrer RI, Ganz T. Inhibition of intracellular Histoplasma capsulatum replication by murine macrophages that produce human defensin. Infect Immun 1994;62:2375-2378.
341. Faurschou M, Sorensen OE, Johnsen AH, Askaa J, Borregaard N. Defensin-rich granules of human neutrophils: characterization of secretory properties. Biochim Biophys Acta 2002;1591:29-35.
342. Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003;422:522-526.
343. Salzman NH, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010;11:76-83.
344. Stappenbeck TS, et al. Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy 2011;7:355-374.
345. Gersemann M, Wehkamp J, Fellermann K, Stange EF. Crohn's disease - defect in innate defence. World J Gastroenterol 2008;14:5499-5503.
346. Wehkamp J, Stange EF. Paneth's disease. J Crohns Colitis 2010;4:523-531.
347. Juste RA. Current strategies for eradication of paratuberculosis and issues in public health. Vet Immunol Immunopathol 2011; doi:.
348. Golde DW. Aetiology of regional enteritis. Lancet 1968;1:1144-1145.
349. Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004;364:1039-1044.
350. Khan KJ, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661-673.
351. Selby WS. Mycobacterium avium subspecies paratuberculosis bacteraemia in patients with inflammatory bowel disease. Lancet 2004;364:1013-1014.
352. Lehrer RI, Barton A, Ganz T. Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry. J Immunol Methods 1988;108:153-158.
353. Kokryakov VN, et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett 1993;327:231-236.
354. Bolintineanu D, Hazrati E, Davis HT, Lehrer RI, Kaznessis YN. Antimicrobial mechanism of pore-forming protegrin peptides: 100 pores to kill E. coli. Peptides 2010;31:1-8.
355. Kagan BL, Ganz T, Lehrer RI. Defensins: a family of antimicrobial and cytotoxic peptides. Toxicology 1994;87:131-149.
356. Mani R, Cady SD, Tang M, Waring AJ, Lehrer RI, Hong M. Membrane-dependent oligomeric structure and pore formation of a beta-hairpin antimicrobial peptide in lipid bilayers from solid-state NMR. Proc Natl Acad Sci USA 2006;103:16242-16247.
357. Wilmes M, Cammue BP, Sahl HG, Thevissen K. Antibiotic activities of host defense peptides: more to it than lipid bilayer perturbation. Nat Prod Rep 2011;28:1350-1358.
358. Schmidt NW, et al. Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization. J Am Chem Soc 2011;133:6720-6727.
359. Miller SI, Pulkkinen WS, Selsted ME, Mekalanos JJ. Characterization of defensin resistance phenotypes associated with mutations in the phoP virulence regulon of Salmonella typhimurium. Infect Immun 1990;58:3706-3710.
360. Prost LR, Sanowar S, Miller SI. Salmonella sensing of anti-microbial mechanisms to promote survival within macrophages. Immunol Rev 2007;219:55-65.
361. Gunn JS, Miller SI. PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance. J Bacteriol 1996;178:6857-6864.
362. Groisman EA, Chiao E, Lipps CJ, Heffron F. Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc Natl Acad Sci USA 1989;86:7077-7081.
363. Peschel A, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001;193:1067-1076.
364. Collins LV, et al. Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J Infect Dis 2002;186:214-219.
365. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004;172:1169-1176.
366. Fedtke I, Gotz F, Peschel A. Bacterial evasion of innate host defenses - the Staphylococcus aureus lesson. Int J Med Microbiol 2004;294:189-194.
367. Ernst CM, et al. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 2009;5:e1000660.
368. Xiao Y, et al. A genome-wide screen identifies a single beta-defensin gene cluster in the chicken: implications for the origin and evolution of mammalian defensins. BMC Genomics 2004;5:56.
369. Jaillon O, et al. Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype. Nature 2004;431:946-957.
370. Schmitt P, Gueguen Y, Desmarais E, Bachere E, de Lorgeril J. Molecular diversity of antimicrobial effectors in the oyster Crassostrea gigas. BMC Evol Biol 2010;10:23.